Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95


Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE.

Alexander BM, Ba S, Berger MS, Berry DA, Cavenee WK, Chang SM, Cloughesy TF, Jiang T, Khasraw M, Li W, Mittman R, Poste GH, Wen PY, Yung WKA, Barker AD; GBM AGILE Network.

Clin Cancer Res. 2018 Feb 15;24(4):737-743. doi: 10.1158/1078-0432.CCR-17-0764. Epub 2017 Aug 16. Review.


Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine.

Zhou X, Liu S, Kim ES, Herbst RS, Lee JJ.

Clin Trials. 2008;5(3):181-93. doi: 10.1177/1740774508091815.


Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial.

Sydes MR, Parmar MK, Mason MD, Clarke NW, Amos C, Anderson J, de Bono J, Dearnaley DP, Dwyer J, Green C, Jovic G, Ritchie AW, Russell JM, Sanders K, Thalmann G, James ND.

Trials. 2012 Sep 15;13:168. doi: 10.1186/1745-6215-13-168.


Antiangiogenic therapy for high-grade glioma.

Khasraw M, Ameratunga MS, Grant R, Wheeler H, Pavlakis N.

Cochrane Database Syst Rev. 2014 Sep 22;(9):CD008218. doi: 10.1002/14651858.CD008218.pub3. Review. Update in: Cochrane Database Syst Rev. 2018 Nov 22;11:CD008218.


Glioblastoma biomarkers from bench to bedside: advances and challenges.

Farias-Eisner G, Bank AM, Hwang BY, Appelboom G, Piazza MA, Bruce SS, Sander Connolly E.

Br J Neurosurg. 2012 Apr;26(2):189-94. doi: 10.3109/02688697.2011.629698. Epub 2011 Dec 17. Review.


Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials.

Ellingson BM, Gerstner ER, Smits M, Huang RY, Colen R, Abrey LE, Aftab DT, Schwab GM, Hessel C, Harris RJ, Chakhoyan A, Gahrmann R, Pope WB, Leu K, Raymond C, Woodworth DC, de Groot J, Wen PY, Batchelor TT, van den Bent MJ, Cloughesy TF.

Clin Cancer Res. 2017 Oct 1;23(19):5745-5756. doi: 10.1158/1078-0432.CCR-16-2844. Epub 2017 Jun 27.


Overview of the epidemiology methods and applications: strengths and limitations of observational study designs.

Colditz GA.

Crit Rev Food Sci Nutr. 2010;50 Suppl 1:10-2. doi: 10.1080/10408398.2010.526838.


The challenges associated with molecular targeted therapies for glioblastoma.

Jue TR, McDonald KL.

J Neurooncol. 2016 May;127(3):427-34. doi: 10.1007/s11060-016-2080-6. Epub 2016 Feb 22. Review.


Trans sodium crocetinate with temozolomide and radiation therapy for glioblastoma multiforme.

Gainer JL, Sheehan JP, Larner JM, Jones DR.

J Neurosurg. 2017 Feb;126(2):460-466. doi: 10.3171/2016.3.JNS152693. Epub 2016 May 13.


Anti-SEMA3A Antibody: A Novel Therapeutic Agent to Suppress Glioblastoma Tumor Growth.

Lee J, Shin YJ, Lee K, Cho HJ, Sa JK, Lee SY, Kim SH, Lee J, Yoon Y, Nam DH.

Cancer Res Treat. 2018 Jul;50(3):1009-1022. doi: 10.4143/crt.2017.315. Epub 2017 Nov 10.


MicroRNAs as biomarkers for human glioblastoma: progress and potential.

Huang SW, Ali ND, Zhong L, Shi J.

Acta Pharmacol Sin. 2018 Sep;39(9):1405-1413. doi: 10.1038/aps.2017.173. Epub 2018 Feb 8. Review.


Prior malignancies in patients harboring glioblastoma: an institutional case-study of 2164 patients.

Zacharia BE, DiStefano N, Mader MM, Chohan MO, Ogilvie S, Brennan C, Gutin P, Tabar V.

J Neurooncol. 2017 Sep;134(2):245-251. doi: 10.1007/s11060-017-2512-y. Epub 2017 May 27. Review.


Multi-omics analysis of primary glioblastoma cell lines shows recapitulation of pivotal molecular features of parental tumors.

Rosenberg S, Verreault M, Schmitt C, Guegan J, Guehennec J, Levasseur C, Marie Y, Bielle F, Mokhtari K, Hoang-Xuan K, Ligon K, Sanson M, Delattre JY, Idbaih A.

Neuro Oncol. 2017 Feb 1;19(2):219-228. doi: 10.1093/neuonc/now160.


NG2 expression in glioblastoma identifies an actively proliferating population with an aggressive molecular signature.

Al-Mayhani MT, Grenfell R, Narita M, Piccirillo S, Kenney-Herbert E, Fawcett JW, Collins VP, Ichimura K, Watts C.

Neuro Oncol. 2011 Aug;13(8):830-45. doi: 10.1093/neuonc/nor088.


A Large-Scale RNAi Screen Identifies SGK1 as a Key Survival Kinase for GBM Stem Cells.

Kulkarni S, Goel-Bhattacharya S, Sengupta S, Cochran BH.

Mol Cancer Res. 2018 Jan;16(1):103-114. doi: 10.1158/1541-7786.MCR-17-0146. Epub 2017 Oct 9.


Clinical practice experience with NovoTTF-100A™ system for glioblastoma: The Patient Registry Dataset (PRiDe).

Mrugala MM, Engelhard HH, Dinh Tran D, Kew Y, Cavaliere R, Villano JL, Annenelie Bota D, Rudnick J, Love Sumrall A, Zhu JJ, Butowski N.

Semin Oncol. 2014 Oct;41 Suppl 6:S4-S13. doi: 10.1053/j.seminoncol.2014.09.010. Epub 2014 Sep 16. Erratum in: Semin Oncol. 2015 Jun;42(3):e33-43.


Electrospun nanofibrous scaffolds increase the efficacy of stem cell-mediated therapy of surgically resected glioblastoma.

Bagó JR, Pegna GJ, Okolie O, Mohiti-Asli M, Loboa EG, Hingtgen SD.

Biomaterials. 2016 Jun;90:116-25. doi: 10.1016/j.biomaterials.2016.03.008. Epub 2016 Mar 9.


Bayesian adaptive randomized trial design for patients with recurrent glioblastoma.

Trippa L, Lee EQ, Wen PY, Batchelor TT, Cloughesy T, Parmigiani G, Alexander BM.

J Clin Oncol. 2012 Sep 10;30(26):3258-63. doi: 10.1200/JCO.2011.39.8420. Epub 2012 May 29.


Towards precision medicine-based therapies for glioblastoma: interrogating human disease genomics and mouse phenotypes.

Chen Y, Gao Z, Wang B, Xu R.

BMC Genomics. 2016 Aug 22;17 Suppl 7:516. doi: 10.1186/s12864-016-2908-7.

Supplemental Content

Support Center